Physician profile
Allyson L Wheaton
NPI 1063491645
$1,749.36
in general payments reported to CMS, 2019-2025
15 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $119 · 2021: $337 · 2022: $381 · 2023: $116 · 2024: $415 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $864.67 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $219.52 | 2019-2024 | Abilify Maintena, Abilify Asimtufii |
| Adlon Therapeutics L.P. | $129.33 | 2020-2021 | |
| Corium, LLC | $114.65 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $84.53 | 2019-2023 | Spravato |
| Teva Pharmaceuticals USA, INC. | $82.72 | 2020-2023 | Austedo Xr |
| Allergan, INC. | $79.43 | 2019 | |
| Ironshore Pharmaceuticals INC. | $45.84 | 2019-2020 | |
| Alkermes, INC. | $21.75 | 2024 | Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $21.40 | 2025 | Cobenfy |
| Brainsway USA INC | $21.32 | 2025 | Deep Tms System |
| Harmony Biosciences LLC | $20.98 | 2023 | Wakix |
| Alfasigma USA, INC. | $17.14 | 2022 | |
| Eisai INC. | $13.86 | 2022 | |
| Neurocrine Biosciences, INC. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Wheaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.